

Virtual Lecture Presentation during Digestive Disease Week® (DDW) 2021

“THE ORAL TISSUE TRANSGLUTAMINASE INHIBITOR ZED1227 PREVENTS GLUTEN-INDUCED ENTEROPATHY IN A TRANSGENIC MOUSE MODEL OF CELIAC DISEASE”.

Speaker: Manuel Encalada Ventura, Mainz, Germany.

The lecture on Zedira’s tissue transglutaminase inhibitor ZED1227 takes place in DDW’s session on **Celiac and Gluten Related Disorders**, on **May 21st, 2021** starting **5:30 PM** Eastern Daylight Time (UTC –4).

During the pre-recorded presentations, the speaker answers to all questions and comments in a chat.

About Zedira:

The German biotech company has a focus on Celiac Disease and other transglutaminase-linked conditions in the arena of autoimmunity, fibrotic diseases, and thrombosis. The company develops, produces, and markets specialty reagents and kits for research and development as well as for clinical diagnostics. Zedira established a pipeline of drug candidates adapted to specific indications based on a series of patented low-molecular transglutaminase blockers. ZED1227 is the first direct-acting transglutaminase inhibitor in clinical development.

This communication is published on April 20th, 2021 by:

Zedira GmbH

Roesslerstr. 83
64293 Darmstadt
Germany

Phone: +49 6151 3251-00

Fax: +49 6151 3251-19

Web: www.zedira.com

E-mail: contact@zedira.com

© 2021, Zedira GmbH